S. Crowe

Type de document

Colloques et conférences (3)

Co-auteur

K. Zaman

R. Von Moos

T. Ruhstaller

B. Thürlimann

R. Stupp

C. Ruegg

C. Rochlitz

C. Mamot

N. Gabriel

S. Aebi

B. Thuerlimann

L. Rossier-Pansier

L. Rossier

O. Pagani

D. Koeberle

L. Jost

Date

Source

Serveur académique Lausannois (3)

Mot-clé

thérapie (3) procès (3) cancer (3) Treatment (3) Cancer (3) Therapeutics (3) Cancer (3) Breast (3) surveillance (2) maladie (2) survie (2) Monitoring (2) Control (2) Methods (2) Survival (2) Patients (2) Molecules (2) Manufacturers' agents (2) Days (2) Commission merchants (2) Cancer--Patients (2) Doxorubicin (2) Bevacizumab (2) Methods (2) Patients (2) maladie (2) toxicité (1) temps (durée) (1) test (1) norme (1)

Documents écrit par S. Crowe (3) | parle de S. Crowe (2)

MMP-9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin. A multicenter, single-arm phase II trial (SAKK24/06). On behalf of the Swiss Group for Clinical Cancer Research (SAKK).

K. Zaman et al. (2010)

hMMP9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin (PLD)

K. Zaman et al. (2010)

Can resistance to trastuzumab be reversed by endocrine therapy? Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with ER-positive, HER-2 positive, advanced breast cancer: a proof-of-concept trial (SAKK 23/03)

D. Koeberle et al. (2010)